Effects of Incretin - based Therapy on High - sensitivity C - reactive Protein in Patients with Type 2 Diabetes: A Systematic Review and Meta - Analysis

• Yucheng Wu ; Yang Shufang ^[1] ; Qingqing Zhang ^[1] ; Lu Yu
  1. [1] Endocrinology, Taizhou People’s Hospital, Taizhou, Jiangsu, China
• Localización: Revista de investigación clínica, ISSN 0034-8376, ISSN-e 2564-8896, Vol. 73, Nº. 2, 2021, págs. 100-110
• Idioma: inglés
• Títulos paralelos:
  • Efectos de la terapia basada en incretinas sobre la proteína C reactiva de alta sensibilidad en pacientes con diabetes tipo 2: revisión sistemática y metanálisis
• Enlaces
  • Texto completo (pdf)
• Resumen
  • español

    Recientemente, los estudios han demostrado que las terapias basadas en incretinas podrían reducir los niveles de marcadores proinflamatorios. Los datos sobre los efectos de las terapias basadas en incretinas sobre la proteína C reactiva de alta sensibilidad (PCR-hs) en la diabetes tipo 2 (DM2) fueron inconsistentes

  • English

    Recently, studies had shown that incretin-based therapies could reduce the levels of pro-inflammatory markers. The data on the effects of incretin-based therapies on serum high-sensitivity C-reactive protein (hs-CRP) in type 2 diabetes (T2DM) were inconsistent. Objective: The objective of the study was to assess the effects of incretin-based therapies on hs- CRP in patients with T2DM by meta-analysis. Methods: We searched PubMed, EMBASE, the Cochrane Collaboration Library, and Web of Science to identify the eligible randomized clinical trials until August 2019. The pooled standard mean differences (SMD) were calculated by random-effects model using STATA 11.0.